TBK1 and neoplasm: Common clinical treatments such as chemoradiotherapy can stimulate the TBK1-IFN pathway to inhibit tumor growth, but it is also necessary to avoid inhibiting the TBK1-IFN pathway that plays an anti-tumor role, such as sorafenib.